The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
The pharma giant leads the pulmonary arterial hypertension pipeline, but other potentially disease-modifying treatments are in the works.
Three new epidermolysis bullosa therapies are approaching the US, and expectations vary wildly.
NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
Attempts to raise a personalised immune response against neoantigens have attracted big pharma interest, most recently from Merck & Co.
Astrazeneca and Ionis’s discontinuation could herald a nervous time for others in this space.